Literature DB >> 25855517

MDM2 antagonist clinical response association with a gene expression signature in acute myeloid leukaemia.

Hua Zhong1, Gong Chen2, Lori Jukofsky3, David Geho3, Sung Won Han4, Fabian Birzele5, Sabine Bader5, Lucia Himmelein5, James Cai6, Zayed Albertyn6, Mark Rothe7, Laurent Essioux8, Helmut Burtscher9, Steven A Middleton3, Ruediger Rueger10, Lin-Chi Chen3, Markus Dangl9, Gwen Nichols3, William E Pierceall3.   

Abstract

Entities:  

Keywords:  MDM2 antagonist; TP53; acute myeloid leukaemia; diagnostic algorithm; gene expression signature

Mesh：

Substances：

Year:  2015        PMID： 25855517      PMCID： PMC5104337          DOI： 10.1111/bjh.13411

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  10 in total

Review 1.  The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor.

Authors:  James J Manfredi
Journal:  Genes Dev       Date:  2010-08-01       Impact factor: 11.361

2.  MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy.

Authors:  Kensuke Kojima; Marina Konopleva; Ismael J Samudio; Masato Shikami; Maria Cabreira-Hansen; Teresa McQueen; Vivian Ruvolo; Twee Tsao; Zhihong Zeng; Lyubomir T Vassilev; Michael Andreeff
Journal:  Blood       Date:  2005-07-12       Impact factor: 22.113

3.  1,25-dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53.

Authors:  Thelma Thompson; Michael Andreeff; George P Studzinski; Lyubomir T Vassilev
Journal:  Mol Cancer Ther       Date:  2010-04-20       Impact factor: 6.261

Review 4.  MDM2 inhibitors for cancer therapy.

Authors:  Lyubomir T Vassilev
Journal:  Trends Mol Med       Date:  2006-11-28       Impact factor: 11.951

Review 5.  Versatile functions of p53 protein in multicellular organisms.

Authors:  P M Chumakov
Journal:  Biochemistry (Mosc)       Date:  2007-12       Impact factor: 2.487

6.  MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.

Authors:  Christian Tovar; Bradford Graves; Kathryn Packman; Zoran Filipovic; Brian Higgins; Mingxuan Xia; Christine Tardell; Rosario Garrido; Edmund Lee; Kenneth Kolinsky; Kwong-Him To; Michael Linn; Frank Podlaski; Peter Wovkulich; Binh Vu; Lyubomir T Vassilev
Journal:  Cancer Res       Date:  2013-02-11       Impact factor: 12.701

Review 7.  Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.

Authors:  Sanjeev Shangary; Shaomeng Wang
Journal:  Annu Rev Pharmacol Toxicol       Date:  2009       Impact factor: 13.820

8.  In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.

Authors:  Lyubomir T Vassilev; Binh T Vu; Bradford Graves; Daisy Carvajal; Frank Podlaski; Zoran Filipovic; Norman Kong; Ursula Kammlott; Christine Lukacs; Christian Klein; Nader Fotouhi; Emily A Liu
Journal:  Science       Date:  2004-01-02       Impact factor: 47.728

9.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.

Authors:  Timothy J Ley; Christopher Miller; Li Ding; Benjamin J Raphael; Andrew J Mungall; A Gordon Robertson; Katherine Hoadley; Timothy J Triche; Peter W Laird; Jack D Baty; Lucinda L Fulton; Robert Fulton; Sharon E Heath; Joelle Kalicki-Veizer; Cyriac Kandoth; Jeffery M Klco; Daniel C Koboldt; Krishna-Latha Kanchi; Shashikant Kulkarni; Tamara L Lamprecht; David E Larson; Ling Lin; Charles Lu; Michael D McLellan; Joshua F McMichael; Jacqueline Payton; Heather Schmidt; David H Spencer; Michael H Tomasson; John W Wallis; Lukas D Wartman; Mark A Watson; John Welch; Michael C Wendl; Adrian Ally; Miruna Balasundaram; Inanc Birol; Yaron Butterfield; Readman Chiu; Andy Chu; Eric Chuah; Hye-Jung Chun; Richard Corbett; Noreen Dhalla; Ranabir Guin; An He; Carrie Hirst; Martin Hirst; Robert A Holt; Steven Jones; Aly Karsan; Darlene Lee; Haiyan I Li; Marco A Marra; Michael Mayo; Richard A Moore; Karen Mungall; Jeremy Parker; Erin Pleasance; Patrick Plettner; Jacquie Schein; Dominik Stoll; Lucas Swanson; Angela Tam; Nina Thiessen; Richard Varhol; Natasja Wye; Yongjun Zhao; Stacey Gabriel; Gad Getz; Carrie Sougnez; Lihua Zou; Mark D M Leiserson; Fabio Vandin; Hsin-Ta Wu; Frederick Applebaum; Stephen B Baylin; Rehan Akbani; Bradley M Broom; Ken Chen; Thomas C Motter; Khanh Nguyen; John N Weinstein; Nianziang Zhang; Martin L Ferguson; Christopher Adams; Aaron Black; Jay Bowen; Julie Gastier-Foster; Thomas Grossman; Tara Lichtenberg; Lisa Wise; Tanja Davidsen; John A Demchok; Kenna R Mills Shaw; Margi Sheth; Heidi J Sofia; Liming Yang; James R Downing; Greg Eley
Journal:  N Engl J Med       Date:  2013-05-01       Impact factor: 91.245

10.  Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.

Authors:  Isabelle Ray-Coquard; Jean-Yves Blay; Antoine Italiano; Axel Le Cesne; Nicolas Penel; Jianguo Zhi; Florian Heil; Ruediger Rueger; Bradford Graves; Meichun Ding; David Geho; Steven A Middleton; Lyubomir T Vassilev; Gwen L Nichols; Binh Nguyen Bui
Journal:  Lancet Oncol       Date:  2012-10-17       Impact factor: 41.316
  10 in total
  9 in total

1.  Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts.

Authors:  Bernhard Reis; Lori Jukofsky; Gong Chen; Giovanni Martinelli; Hua Zhong; W Venus So; Michael J Dickinson; Mark Drummond; Sarit Assouline; Maneja Hashemyan; Michel Theron; Steven Blotner; Je-Hwan Lee; Margaret Kasner; Sung-Soo Yoon; Ruediger Rueger; Karen Seiter; Steven A Middleton; Kevin R Kelly; Norbert Vey; Karen Yee; Gwen Nichols; Lin-Chi Chen; William E Pierceall
Journal:  Haematologica       Date:  2016-02-11       Impact factor: 9.941

Review 2.  Pharmacological activation of wild-type p53 in the therapy of leukemia.

Authors:  Kensuke Kojima; Jo Ishizawa; Michael Andreeff
Journal:  Exp Hematol       Date:  2016-06-18       Impact factor: 3.084

3.  Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition.

Authors:  Jo Ishizawa; Kenji Nakamaru; Takahiko Seki; Koichi Tazaki; Kensuke Kojima; Dhruv Chachad; Ran Zhao; Lauren Heese; Wencai Ma; Man Chun John Ma; Courtney DiNardo; Sherry Pierce; Keyur P Patel; Archie Tse; R Eric Davis; Arvind Rao; Michael Andreeff
Journal:  Cancer Res       Date:  2018-02-28       Impact factor: 12.701

4.  p52-ZER6: a determinant of tumor cell sensitivity to MDM2-p53 binding inhibitors.

Authors:  Wen-Fang Li; Leader Alfason; Can Huang; Yu Tang; Li Qiu; Makoto Miyagishi; Shou-Rong Wu; Vivi Kasim
Journal:  Acta Pharmacol Sin       Date:  2022-08-22       Impact factor: 7.169

Review 5.  Targeting p53-MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials.

Authors:  Haohao Zhu; Hui Gao; Yingying Ji; Qin Zhou; Zhiqiang Du; Lin Tian; Ying Jiang; Kun Yao; Zhenhe Zhou
Journal:  J Hematol Oncol       Date:  2022-07-13       Impact factor: 23.168

6.  miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia.

Authors:  Timothy J Molloy; David D Ma; Thi Thanh Vu; Friedrich Stölzel; Kristy W Wang; Christoph Röllig; Melinda L Tursky
Journal:  Leukemia       Date:  2020-12-01       Impact factor: 11.528

Review 7.  The Role of p53 Signaling in Colorectal Cancer.

Authors:  Magdalena C Liebl; Thomas G Hofmann
Journal:  Cancers (Basel)       Date:  2021-04-28       Impact factor: 6.639

8.  Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.

Authors:  Arman Esfandiari; Thomas A Hawthorne; Sirintra Nakjang; John Lunec
Journal:  Mol Cancer Ther       Date:  2016-02-01       Impact factor: 6.261

9.  Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.

Authors:  Michael Andreeff; Kevin R Kelly; Karen Yee; Sarit Assouline; Roger Strair; Leslie Popplewell; David Bowen; Giovanni Martinelli; Mark W Drummond; Paresh Vyas; Mark Kirschbaum; Swaminathan Padmanabhan Iyer; Vivian Ruvolo; Graciela M Nogueras González; Xuelin Huang; Gong Chen; Bradford Graves; Steven Blotner; Peter Bridge; Lori Jukofsky; Steve Middleton; Monica Reckner; Ruediger Rueger; Jianguo Zhi; Gwen Nichols; Kensuke Kojima
Journal:  Clin Cancer Res       Date:  2015-10-12       Impact factor: 12.531
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.